Rain Therapeutics Inc. announced addition of Lori Kunkel to its scientific advisory board. Dr. Kunkel is a clinical drug development specialist and strategic advisor to targeted and immuno-oncology biotechnology companies with over twenty years of experience in the oncology space. Dr. Kunkel currently serves on the board of directors of Loxo Oncology Inc., Curis Inc., Maverick Therapeutics Inc.,and Tocagen Inc. Previously she has served as acting chief medical officer of Loxo Oncology Inc., chief medical officer of Pharmacyclics, LLC, and Proteolix Inc. and vice president of clinical development at Xencor Inc. Earlier in her career she was a clinical scientist at Genentech, where she worked on the development of RITUXAN. Prior to her career in biotechnology, Dr. Kunkel spent a decade in academic medicine as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles. She received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and has held board certifications in hematology and oncology.